Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update

dc.contributor.authorBlanco Guillermo, Ignacio
dc.contributor.authorBueno, Patricia
dc.contributor.authorDiego, Isidro
dc.contributor.authorPérez-Holanda, Sergio
dc.contributor.authorCasas-Maldonado, Francisco
dc.contributor.authorEsquinas López, Cristina
dc.contributor.authorMiravitlles Fernández, Marc
dc.date.accessioned2022-10-31T19:05:53Z
dc.date.available2022-10-31T19:05:53Z
dc.date.issued2017-06-08
dc.date.updated2022-10-31T19:05:53Z
dc.description.abstractIn alpha-1 antitrypsin deficiency (AATD), the Z allele is present in 98% of cases with severe disease, and knowledge of the frequency of this allele is essential from a public health perspective. However, there is a remarkable lack of epidemiological data on AATD worldwide, and many of the data currently used are outdated. Therefore, the objective of this study was to update the knowledge of the frequency of the Z allele to achieve accurate estimates of the prevalence and number of Pi*ZZ genotypes worldwide based on studies performed according to the following criteria: 1) samples representative of the general population, 2) AAT phenotyping characterized by adequate methods, and 3) measurements performed using a coefficient of variation calculated from the sample size and 95% confidence intervals. Studies fulfilling these criteria were used to develop maps with an inverse distance weighted (IDW)-interpolation method, providing numerical and graphical information of Pi*Z distribution worldwide. A total of 224 cohorts from 65 countries were included in the study. With the data provided by these cohorts, a total of 253,404 Pi*ZZ were estimated worldwide: 119,594 in Europe, 91,490 in America and Caribbean, 3,824 in Africa, 32,154 in Asia, 4,126 in Australia, and 2,216 in New Zealand. In addition, the IDW-interpolation maps predicted Pi*Z frequencies throughout the world even in some areas that lack real data. In conclusion, the inclusion of new well-designed studies and the exclusion of the low-quality ones have significantly improved the reliability of results, which may be useful to plan strategies for future research and diagnosis and to rationalize the therapeutic resources available.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec678826
dc.identifier.issn1176-9106
dc.identifier.pmid28243076
dc.identifier.urihttps://hdl.handle.net/2445/190359
dc.language.isoeng
dc.publisherDove Medical Press
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.2147/COPD.S125389
dc.relation.ispartofInternational Journal of Chronic Obstructive Pulmonary Disease, 2017, vol. 12, p. 1683-1694
dc.relation.urihttps://doi.org/10.2147/COPD.S125389
dc.rightscc-by-nc (c) Blanco Guillermo, Ignacio et al., 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourceArticles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)
dc.subject.classificationMalalties hereditàries
dc.subject.classificationEpidemiologia genètica
dc.subject.classificationSistemes d'informació geogràfica
dc.subject.classificationInhibidors enzimàtics
dc.subject.otherGenetic diseases
dc.subject.otherGenetic epidemiology
dc.subject.otherGeographic information systems
dc.subject.otherEnzyme inhibitors
dc.titleAlpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
678826.pdf
Mida:
11.09 MB
Format:
Adobe Portable Document Format